Bristol's Abilify gets expanded FDA approval

02/28/2008 | Bloomberg

Abilify, an antipsychotic drug from Bristol-Myers Squibb Co., has received additional FDA clearance for the treatment of bipolar disorder in children 10 years and older. The company currently markets the drug for schizophrenia patients aged 13 and up and adults with bipolar disorder and major depression.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT